Forte Biosciences, Inc.
FB102
celiac disease
Countdown
177days
Phase 2 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 2 trial results for FB102 in celiac disease are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“The topline results from our phase 2 celiac disease study are expected in 2026.”